- Home
- SFWL vs CLYM Comparison
SFWL vs CLYM Comparison
Compare SFWL & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFWL
- CLYM
- Stock Information
- Founded
- SFWL 2001
- CLYM 2018
- Country
- SFWL China
- CLYM United States
- Employees
- SFWL N/A
- CLYM N/A
- Industry
- SFWL Trucking Freight/Courier Services
- CLYM
- Sector
- SFWL Industrials
- CLYM
- Exchange
- SFWL Nasdaq
- CLYM NYSE
- Market Cap
- SFWL 82.3M
- CLYM 83.8M
- IPO Year
- SFWL 2023
- CLYM 2021
- Fundamental
- Price
- SFWL $0.99
- CLYM $1.45
- Analyst Decision
- SFWL
- CLYM Buy
- Analyst Count
- SFWL 0
- CLYM 1
- Target Price
- SFWL N/A
- CLYM $10.00
- AVG Volume (30 Days)
- SFWL 13.0K
- CLYM 211.6K
- Earning Date
- SFWL 09-04-2025
- CLYM 08-13-2025
- Dividend Yield
- SFWL N/A
- CLYM N/A
- EPS Growth
- SFWL 4.79
- CLYM N/A
- EPS
- SFWL 0.13
- CLYM N/A
- Revenue
- SFWL $504,158,000.00
- CLYM N/A
- Revenue This Year
- SFWL N/A
- CLYM N/A
- Revenue Next Year
- SFWL N/A
- CLYM N/A
- P/E Ratio
- SFWL $7.48
- CLYM N/A
- Revenue Growth
- SFWL 24.75
- CLYM N/A
- 52 Week Low
- SFWL $0.86
- CLYM $1.05
- 52 Week High
- SFWL $1.60
- CLYM $8.79
- Technical
- Relative Strength Index (RSI)
- SFWL 51.50
- CLYM N/A
- Support Level
- SFWL $0.95
- CLYM N/A
- Resistance Level
- SFWL $1.02
- CLYM N/A
- Average True Range (ATR)
- SFWL 0.03
- CLYM 0.00
- MACD
- SFWL 0.00
- CLYM 0.00
- Stochastic Oscillator
- SFWL 72.80
- CLYM 0.00
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.